![Paolo Bernardi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Federica Draghi | M | - |
Congenia Srl
![]() Congenia Srl Miscellaneous Commercial ServicesCommercial Services Congenia SRL operates as pharmaceutical company, is engaged in the development of novel therapeutics for diseases associated with mitochondrial stress-induced dysfunction. The company develops small molecule drugs that target the mitochondrial permeability transition pore, a protein channel with various macromolecular components that along with mitochondrial protein p66, appears to be associated with oxidative stress-induced cell death. The company was founded in 2004 by Saverio Minucci, Pier Giuseppe Pelicci, Marco Giorgio and Paolo Bernardi and is headquartered in Milan, Italy. | 20 Jahre |
Marco Giorgio | M | - |
Congenia Srl
![]() Congenia Srl Miscellaneous Commercial ServicesCommercial Services Congenia SRL operates as pharmaceutical company, is engaged in the development of novel therapeutics for diseases associated with mitochondrial stress-induced dysfunction. The company develops small molecule drugs that target the mitochondrial permeability transition pore, a protein channel with various macromolecular components that along with mitochondrial protein p66, appears to be associated with oxidative stress-induced cell death. The company was founded in 2004 by Saverio Minucci, Pier Giuseppe Pelicci, Marco Giorgio and Paolo Bernardi and is headquartered in Milan, Italy. | 20 Jahre |
Pier Giuseppe Pelicci | M | - |
Congenia Srl
![]() Congenia Srl Miscellaneous Commercial ServicesCommercial Services Congenia SRL operates as pharmaceutical company, is engaged in the development of novel therapeutics for diseases associated with mitochondrial stress-induced dysfunction. The company develops small molecule drugs that target the mitochondrial permeability transition pore, a protein channel with various macromolecular components that along with mitochondrial protein p66, appears to be associated with oxidative stress-induced cell death. The company was founded in 2004 by Saverio Minucci, Pier Giuseppe Pelicci, Marco Giorgio and Paolo Bernardi and is headquartered in Milan, Italy. | 20 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Paolo Fundarò | M | 50 |
Congenia Srl
![]() Congenia Srl Miscellaneous Commercial ServicesCommercial Services Congenia SRL operates as pharmaceutical company, is engaged in the development of novel therapeutics for diseases associated with mitochondrial stress-induced dysfunction. The company develops small molecule drugs that target the mitochondrial permeability transition pore, a protein channel with various macromolecular components that along with mitochondrial protein p66, appears to be associated with oxidative stress-induced cell death. The company was founded in 2004 by Saverio Minucci, Pier Giuseppe Pelicci, Marco Giorgio and Paolo Bernardi and is headquartered in Milan, Italy. | - |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Italien | 4 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Paolo Bernardi
- Persönliches Netzwerk